CompletedPhase 2NCT03841526
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
Studying Exercise-induced hyperinsulinism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xeris Pharmaceuticals
- Principal Investigator
- Khaled Junaidi, MDXeris Pharmaceuticals
- Intervention
- Glucagon RTU Injection With Insulin Pump Reduction(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2019 – 2020
Study locations (1)
- LMC Clinical Research Inc, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03841526 on ClinicalTrials.gov